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Background: Resection margin status has traditionally been associated with tumor recurrence and
oncological outcome following liver resection for colorectal liver metastases. Previous studies, however,
did not address the impact of resection margin on the site of tumor recurrence and did not differentiate
between true local recurrence at the resection margin and recurrence elsewhere in the liver. This study
aimed to determine whether positive resection margins determine local recurrence and whether
recurrence at the surgical margin influences long-term survival.
Methods: Clinicopathological data and oncological outcomes of patients who underwent curative
resection for colorectal liver metastases between 2012 and 2017 at 2 major hepatobiliary centers (Bern,
Switzerland, and Berlin, Germany) were assessed. Cross-sectional imaging following hepatectomy was
reviewed by radiologists in both centers to distinguish between recurrence at the resection margin,
defined as hepatic local recurrence, and intrahepatic recurrence elsewhere. The association between
surgical margin status and location of tumor recurrence was evaluated, and the impact on overall sur-
vival was determined.
Results: During the study period, 345 consecutive patients underwent hepatectomy for colorectal liver
metastases. Histologic surgical margins were positive for tumor cells (R1) in 63 patients (18%). After a
median follow-up time of 34 months, tumor recurrence was identified in 154 patients (45%). Hepatic local
recurrence was not detected more frequently after R1 than after R0 resection (P ¼ .555). Hepatic local
recurrence was not associated with worse overall survival (P ¼ .436), while R1 status significantly impaired
overall survival (P ¼ .025). Additionally, overall survival was equivalent between patients with hepatic local
recurrence and patients with any intrahepatic and/or extrahepatic recurrence. In patients with intrahepatic
recurrence only, oncological outcomes improved if local hepatic therapy was possible (resection or
ablation) in comparison to patients treated only with chemotherapy or best supportive care (3-year overall
survival: 85% vs 39%; P < .0001).
Conclusion: The incidence of hepatic local recurrence after hepatectomy for colorectal liver metastases is
independent of R1 resection margin status. Additionally, hepatic local recurrence at the resection margin
is not associated with worse overall survival compared with any other intra- or extrahepatic recurrence.
Therefore, R1 status at hepatectomy seems to be a surrogate factor for advanced disease withouted equally as first authors.
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making when extending the indication for surgery in borderline resectable colorectal liver metastases.
© 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
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Liver resection may improve the oncological outcome of pa-
tients with colorectal liver metastases (CRLM) and is associated
with 5-year overall survival (OS) rates of up to 58% within the
framework of multimodal treatment strategies including modern
systemic therapy.1,2 Resectability rates and oncological outcome
have increasingly improved in recent years owing to advances in
surgical techniques,3,4 preoperative imaging,5 interventional radi-
ology,6 perioperative management,7 and systemic therapy.8,9 In
particular, parenchymal-sparing liver resection allowed for an in-
crease in resectability.10 Increasing implementation of
parenchymal-sparing hepatectomy, however, potentially increases
the risk for local recurrence.11 Despite state-of-the-art treatment, a
significant proportion of patients undergoing hepatectomy for
CRLM, (between 45%12 and 70%13), suffer from tumor recurrence.
Nevertheless, in case of intrahepatic recurrence,14 favorable out-
comes are still achievable, especially if repeat hepatectomy is
technically feasible.15
Previous authors have suggested that histologically positive
resection margins (R1 resection: tumor free margin <1 mm) are
associated with higher recurrence rates, lower disease-free sur-
vival, and worse OS.16e18 R1 resection has also been associated with
higher surgical margin recurrence during an older era lacking
standardized perioperative chemotherapy with modern cytotoxic
and biological agents.19 Therefore, one of the criteria used to select
patients for hepatectomy for CRLM has traditionally been the pre-
dicted ability to achieve pathologically negative surgical margins.
However, survival is not only a function of technically feasible
resectability but is also dependent on biological aggressiveness,
which translates into the presence of somatic gene mutations.20
Thus, it remains unclear if R1 resection margin only represents a
surrogate factor of advanced disease while not determining the
location of recurrence. Importantly, current studies examining tu-
mor recurrence patterns following hepatectomy for CRLM did not
differentiate between true local recurrence at the resection margin
and recurrence elsewhere in the liver and thus could not
adequately evaluate the effect of marginal tumor relapse on
oncological outcome.21
Our study defined the association between surgical margin
status (R0 versus R1) and location of tumor recurrence (hepatic
surgical margin versus intrahepatic recurrence versus extrahepatic
recurrence). We further assessed the impact of margin status and
location of recurrence on OS in patients undergoing curative-
intended hepatectomy for CRLM.Materials and methods
Patient inclusion criteria
This study was initiated after obtaining approval from the Ethics
Committee of the Canton of Bern (2018-01576) and the Ethics
Committee of the ChariteeUniversit€atsmedizin Berlin (EA2/006/
16). Clinicopathological data from 345 consecutive patients who
underwent resection for CRLM from 2012 to 2017 at the Depart-
ment of Visceral Surgery und Medicine, lnselspital, Bern University
Hospital or the Department of Surgery, Campus Charite Mitte andCampus Virchow Klinikum, ChariteeUniversit€atsmedizin Berlin
were evaluated.
Patients were included in the analysis if curative-intended
resection, defined as the ability to remove all radiologically
evident disease, was performed. Patients were excluded if they
were <18 years old, or if microwave ablation was performed
concomitant to surgery.
Preoperative assessment
Patients with CRLM were evaluated preoperatively in each
center according to standardized protocols, including medical his-
tory, physical examination, serum laboratory tests, and an anes-
thesia evaluation. The extent of disease, type of resection, and the
future liver remnant (FLR) volume were assessed using cross-
sectional imaging (triphasic contrast-enhanced computed tomog-
raphy or magnetic resonance imaging with liver-specific contrast
agents).
Weekly multidisciplinary tumor boards in each center attended
by hepatobiliary surgeons, hepatologists, oncologists, radiologists,
and pathologists found a consensus on the best individual treat-
ment strategy for each patient. Hepatectomy was recommended if
CRLM could be resected with preservation of a sufficient FLR. In
patients with an anticipated insufficient FLR volume, preoperative
portal vein embolization22 or associating liver partition and portal
vein ligation procedure4 was performed to induce hypertrophy of
the FLR and enable safe resection.
Surgical procedure and postoperative management
Following laparotomy or laparoscopy, the peritoneal cavity was
examined to exclude peritoneal deposits. Intraoperative ultrasound
of the liver was performed to identify the exact location of CRLM
and their proximity to portal pedicles and hepatic veins and thus
guide resection. Total or selective hepatic vascular exclusion was
performed for major parenchymal transections, as needed.23 Major
hepatectomywas defined as resection of 3 or more continuous liver
segments according to the Couinaud classification.24
Following hepatectomy, patients were monitored for post-
operative complications according to the institutional standards.
Postoperative morbidity was defined as any complicationwithin 90
days after surgery and was graded according to the classification of
Clavien and Dindo.25 Major morbidity was defined as any compli-
cation 3a grade and postoperative mortality as grade 5. All pa-
tients were assessed again postoperatively at the multidisciplinary
tumor board to discuss the need for any additional treatment
versus tumor surveillance alone according to international
guidelines.26
Histologic evaluation
Resected specimens were subjected to histologic evaluation to
confirm the diagnosis of CRLM and determine the resection margin
status. R1 resection was defined as the microscopic presence of
tumor cells within 1 mm from the transection line, whereas R0
resection was defined as complete tumor resection with no tumor
cells within 1 mm of the resection margin as previously
described.18
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Tumor recurrence was defined as the first tumor relapse after
curative-intended hepatectomy for CRLM. For this study, cross-
sectional imaging performed during the scheduled long-term
oncologic surveillance after hepatectomy was reviewed by a radi-
ologist in each center, blinded to the clinical outcomes, to identify
the presence and location of recurrent disease. Cross-sectional
imaging after surgery was scheduled every 3 months in the first
2 years and then every 12 months.
For this manuscript, the following definitions of recurrence
location were used: true local recurrence at the liver resection
margin defined as hepatic local recurrence (H-LR), intrahepatic
recurrence not at the resection margin defined as hepatic nonlocal
recurrence, and extrahepatic recurrence. The definition of any
recurrence included all patients with recurrent disease at any
intrahepatic and/or extrahepatic site, excluding patients with H-LR
only. H-LR was defined as recurrent disease within 1 cm from the
transection line in cross-sectional imaging.Statistical analysis
Quantitative and qualitative variables were expressed as me-
dians (range) and frequencies (percentage). Comparisons between
groups were analyzedwith the c2 or Fisher exact test for categorical
variables and the Mann-Whitney U test for continuous variables, as
appropriate. To identify factors associated with R1 resection, the
following parameters were analyzed in univariate analysis:
administration of preoperative chemotherapy, extent of hepatec-
tomy, major versus minor liver resection, open versus laparoscopic
hepatectomy, use of parenchyma-sparing resection, 90-day overall
postoperative morbidity, 90-day major postoperative morbidity,
90-day postoperative mortality, and administration of post-
operative chemotherapy. All factors with P < .100 in univariate
analysis were then entered in a logistic regression model with
backward elimination. Using the Kaplan-Meier method, OS was
calculated from the date of resection to the date of death or last
follow-up. Comparisons between survival rates were performed
using log-rank tests. Multivariate analysis was performed to iden-
tify factors that are independently associated with OS using a Cox
regression model with backward elimination by entering all pa-
rameters with P < .100 in the univariate analysis. P values < .05
were considered statistically significant. Statistical analyses were
performed using the SPSS software package, version 25 (IBM,
Armonk, NY).Results
Patient characteristics
During the study period, 345 patients underwent liver resection
for CRLM with curative intent in both centers. Histologic surgical
margins were positive for tumor cells (R1) in 63 patients (18%) and
negative in 282 patients. Close proximity to large vessels that could
not be sacrificed for tumor-free margins were found in 30 out of 63
R1-resected patients (48%).
R1 resection was associated with worse OS compared with R0
resection (3-year OS: 40% vs 71%; P < .0001, Fig 1). Additionally, R1
resection correlated with more major resections (60.3% vs 45.0%;
P ¼ .028), less minimal-invasive hepatectomies (6.3% vs 25.5%;
P ¼ .001), increased postoperative morbidity (63.5% vs 41.1%;
P ¼ .001), and mortality (9.5% vs 2.5%; P ¼ .018, Table I). In multi-
variate analysis, open hepatectomy (odds ratio 5.0, 95% confidence
interval [CI] 1.4e10.0; P ¼ .006) and postoperative morbidity (oddsratio 2.2, 95% CI 1.2e3.9; P ¼ .007) were independently associated
with R1 resection (Table I).
Tumor recurrence
Tumor recurrence was identified in 154 patients (45%) after a
median follow-up time of 34 months. Median time to recurrence
was 18 months. Characteristics of patients stratified according to
the location of recurrence (H-LR versus any recurrence) are sum-
marized in Table II. Clinicopathological parameters were not
different between the 2 groups. Margin status was not associated
with the location of recurrence, both intra- and extrahepatic (P ¼
.748, Table III). H-LR was not detected more frequently after R1
resection than after R0 resection (17.9% vs 13.5%; P ¼ .555). For a
better understanding of how the location of CRLM affected the site
of recurrence following R1 resection, we divided the R1 cohort
among patients with recurrence (n ¼ 28, Table III) in centrally
located CRLM with proximity to large vessels (R1c, n ¼ 16 [57%])
and subcapsular, superficially located (R1s, n ¼ 12 [43%]) CRLM.
There was no association between the location of CRLM and the
incidence of recurrence (P ¼ .288, Table III) after R1 resection.
Location of recurrence and overall survival
OS was not different between H-LR only and other combination
of intrahepatic recurrence (hepatic nonlocal recurrence ± H-LR) (3-
year OS: 78% vs 55%; P¼ .436, Fig 2). OS was also not different when
comparing patients with H-LR only and patients with any recur-
rence (intrahepatic and/or extrahepatic) (3-year OS: 78% vs 64%;
P ¼ .454, Fig 3).
We additionally performed univariate and multivariate analysis
to identify factors associated with OS following hepatectomy for
CRLM including both H-LR versus other sites of recurrence versus
no recurrence and R1 versus R0. The results are summarized in
Supplementary Table S1. The multivariate analysis indicated that
the site of recurrence was not associated with OS, whereas R1
status independently predicted worse OS (hazard ratio 2.1, 95% CI
1.3e3.4; P ¼ .003).
Survival analysis according to the treatment for the recurrent
disease showed that local therapy (repeat hepatectomy or ablation)
for intrahepatic recurrence improved OS compared with palliative
chemotherapy or best supportive care irrespective of whether
intrahepatic and/or extrahepatic recurrence was present. Patients
with intrahepatic recurrent disease undergoing local hepatic ther-
apy had a significantly better 3-year OS compared with patients not
able to receive repeat hepatectomy or ablation (85% vs 39%; P <
.0001, Fig 4). In patients with intrahepatic and concomitant extra-
hepatic disease, the survival difference in favor of local liver-
directed treatment did not reach statistical significance (3-year
OS: 67% vs 59%; P ¼ .152).
Discussion
This multi-institutional study demonstrated that R1 margin
status was not associated with H-LR following curative-intended
hepatectomy for CRLM. In contrast to R1 status, H-LR was not
associated with worse OS. Our current study supports the hy-
pothesis that R1 resection is more of a surrogate factor for advanced
disease and not a determinant of recurrence pattern, as it was
associated with the extent of resection and surgical postoperative
outcomes but not the location of recurrent disease.
Previous studies have investigated the impact of histologically
positive resection margins on recurrence probability and long-term
survival after resection for CRLM. However, many of these studies
are older than 10 years and thereby cannot assess the latest
Fig 1. Overall survival according to margin status after liver resection for CRLM (n ¼ 345). CRLM, colorectal liver metastases.
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proposed R1 resection as a predictor of worse outcome did not
assess its impact on local recurrence at the resection margin.16,17,19
The only study so far that also distinguished between recurrence at
the surgical margin and recurrence elsewhere in the liver showing
a significant association between R1 status and H-LR was per-
formed in 2005.19 In this study, no preoperative chemotherapy was
reported and adjuvant chemotherapy regimens belonged to an era
before the establishment of modern cytotoxic agents and mono-
clonal antibodies.8,9 The benefits of perioperative chemotherapy
with FOLFOX have been known since the European Organisation forTable I
Univariate and multivariate analysis of factors associated w
resection for CRLM
R0 (n ¼ 282
Preoperative chemotherapy, n (%) 157 (55.7)
PVE, n (%) 23 (8.2)
ALPPS procedure, n (%) 2 (0.7)
Surgical technique, n (%)
Right hepatectomy 65 (23.0)
Left hepatectomy 22 (7.8)
Extended right hepatectomy 35 (12.4)
Extended left hepatectomy 6 (2.1)
Left lateral hepatectomy 17 (6.0)
Wedge resection 102 (36.2)
Bisegmentectomy 35 (12.4)
Major liver resection, n (%) 127 (45.0)
Open hepatectomy, n (%) 210 (74.5)
Parenchymal-sparing resection, n (%) 139 (48.4)
90-d postoperative morbidity, n (%) 116 (41.1)
90-d major postoperative morbidity, n (%) 68 (24.1)
90-d postoperative mortality, n (%) 7 (2.5)
Postoperative chemotherapy, n (%) 99 (35.1)
ALPPS, associating liver partition and portal vein ligation f
colorectal liver metastases;MV,multivariate analysis;NS, not
UV, univariate analysis.
* Logistic regression multivariate analysis included all variResearch and Treatment of Cancer study.8 Within this setting,
adjuvant systemic therapy after neoadjuvant chemotherapy and
hepatectomy for CRLM may improve disease-free survival. Addi-
tionally, this study probably did not include any patients treated
within the framework of modern parenchymal-sparing concepts,
which have been increasingly implemented in our practice. In a
more recent study, positive surgical margins were not associated
with increased marginal recurrence despite more frequent intra-
hepatic recurrence.27 In addition, multiple indicators supporting
surgical margins as a surrogate factor of advanced disease were
identified in this study, such as the association of R1 status withith R1 resection in 345 patients who underwent liver
) R1 (n ¼ 63) UV MV*
P P OR (95% CI)
31 (49.2) .351










38 (60.3) .028 NS
59 (93.7) .001 .006 5.0 (1.4e10.0)
25 (37.9) .121
40 (63.5) .001 .007 2.2 (1.2e3.9)
20 (31.7) .209
6 (9.5) .018 NS
19 (30.2) .454
or staged hepatectomy; CI, confidence interval; CRLM,
significant; OR, odds ratio; PVE, portal vein embolization;
ables with P < .100 in univariate analysis.
Table II
Clinicopathological data of 345 patients who underwent liver resection for CRLM according to tumor recurrence location
Variable H-LR (n ¼ 22) Any recurrence* (n ¼ 132) No recurrence (n ¼ 191) All patients (n ¼ 345) P
Sex, n (%) .944
Female 7 (31.8) 43 (32.6) 65 (34.0) 115 (33.3)
Male 15 (68.2) 89 (67.4) 126 (66.0) 230 (66.7)
Age, y, median (range) 68 (47e77) 61 (26e83) 65 (25e89) 64 (25e89) .067
Age >65 y n (%) 12 (54.5) 52 (39.4) 93 (48.7) 157 (45.5) .182
BMI, kg/m2, median (range) 24.45 (18e35) 25.25 (17e46) 25.18 (17e43) 25.05 (17e46) .607
BMI >30 kg/m2, n (%) 4 (18.2) 21 (15.9) 36 (19.7) 61 (18.1) .759
ASA physical status, n (%) .088
1 0 (0.0) 3 (2.3) 3 (1.6) 6 (1.7)
2 14 (63.6) 68 (51.5) 83 (43.5) 165 (47.8)
3 6 (27.3) 59 (44.7) 103 (53.9) 168 (48.7)
4 2 (9.1) 2 (1.5) 2 (1.0) 6 (1.7)
Diabetes, n (%) 5 (22.7) 14 (10.6) 33 (17.3) 52 (15.1) .153
Hypertension, n (%) 7 (31.8) 50 (37.9) 84 (44.0) 141 (40.9) .586
Coronary heart disease, n (%) 1 (4.5) 7 (5.3) 17 (8.9) 25 (7.2) 1
Pulmonary disease, n (%) 1 (4.5) 7 (5.3) 17 (8.9) 25 (7.2) 1
Renal disease, n (%) 8 (0.0) 6 (4.5) 18 (9.4) 24 (7.0) .595
Location of primary tumor, n (%) .674
Right hemicolon 6 (27.3) 27 (20.5) 40 (20.9) 73 (21.2)
Left hemicolon/sigmoid 8 (36.4) 45 (34.1) 71 (37.2) 124 (35.9)
Rectum 8 (36.4) 60 (45.5) 80 (41.9) 148 (42.9)
Synchronous CRLM, n (%) 14 (63.6) 81 (61.4) 94 (49.2) 189 (54.8) .839
Size of largest CRLM >50 mm, n (%) 7 (33.3) 39 (32.5) 47 (25.7) 93 (28.7) .940
Solitary CRLM, n (%) 8 (36.4) 41 (31.3) 69 (36.3) 118 (34.4) .637
Preoperative chemotherapy, n (%) 16 (72.7) 87 (65.9) 85 (44.5) 188 (54.5) .529
T stage of primary, n (%) .190
1 0 (0.0) 8 (6.6) 8 (4.6) 16 (5.1)
2 2 (9.1) 12 (9.9) 22 (12.8) 36 (11.4)
3 17 (77.3) 66 (54.6) 115 (66.9) 198 (62.9)
4 3 (13.6) 35 (28.9) 27 (15.7) 65 (20.6)
N stage of primary, n (%) .091
0 12 (54.6) 39 (31.7) 69 (40.1) 120 (37.9)
1 7 (31.8) 47 (38.2) 56 (32.6) 110 (34.7)
2 3 (13.6) 37 (30.1) 46 (26.7) 86 (27.1)
3 0 (0.0) 0 (0.0) 1 (0.6) 1 (0.3)
UICC stage of primary, n (%) .631
1 1 (4.6) 11 (8.4) 20 (10.9) 32 (9.5)
2 3 (13.6) 11 (8.4) 28 (15.2) 42 (12.5)
3 3 (13.6) 29 (22.1) 37 (20.1) 69 (20.5)
4 15 (68.2) 80 (61.1) 99 (53.8) 194 (57.5)
Tumor grading of primary, n (%) .704
G1 1 (6.7) 5 (5.6) 2 (1.5) 8 (3.3)
G2 13 (86.6) 71 (79.8) 119 (85.6) 203 (83.5)
G3 1 (6.7) 13 (14.6) 18 (12.9) 32 (13.2)
Length of ICU stay, d, median (range) 2 (0e9) 1 (0e7) 1 (0e51) 1 (0e51) .147
Duration of hospital stay, d, median (range) 9.5 (5e37) 10 (2e109) 10 (2e87) 10 (2e109) .855
90-d complications, n (%) 14 (63.6) 49 (37.1) 93 (48.7) 156 (45.2) .019
90-d major complications, n (%) 6 (27.3) 25 (18.9) 57 (29.8) 88 (25.5) .392
90-d mortality, n (%) 0 (0.0) 1 (0.8) 12 (6.3) 13 (3.8) 1
Anatomical resection, n (%) 15 (68.2) 83 (62.9) 118 (61.8) 216 (62.6) .632
Major resection, n (%) 13 (59.1) 62 (47.0) 90 (47.1) 165 (47.8) .292
Minimally invasive hepatectomy, n (%) 4 (18.2) 17 (12.9) 55 (28.8) 76 (22.0) .506
Positive resection margins, n (%) 5 (22.7) 23 (17.4) 35 (18.3) 63 (18.3) .555
Surgical technique, n (%) .121
Right hepatectomy 9 (40.9) 29 (22.0) 42 (22.0) 80 (23.2)
Left hepatectomy 3 (13.6) 8 (6.1) 19 (9.9) 30 (8.7)
Extended right hepatectomy 1 (4.5) 20 (15.2) 25 (13.1) 46 (13.3)
Extended left hepatectomy 0 (0.0) 6 (4.5) 4 (2.1) 10 (2.9)
Left lateral hepatectomy 1 (4.5) 9 (6.8) 8 (4.2) 18 (5.2)
Wedge resection 8 (36.4) 42 (31.8) 70 (36.6) 120 (34.8)
Bisegmentectomy 0 (0.0) 18 (13.6) 23 (12.0) 41 (11.9)
Need for intraoperative RBC transfusion, n (%) 4 (18.2) 32 (24.2) 37 (19.4) 73 (21.2) .534
Length of operation, min, median (range) 239 (75e469) 262 (30e820) 237 (46e766) 249 (30e820) .377
Surgical liver site infection, n (%) 4 (18.2) 5 (3.8) 16 (8.4) 25 (7.2) .025
Postoperative chemotherapy, n (%) 9 (40.9) 70 (53.0) 39 (20.4) 118 (34.2) .292
P: comparison between hepatic local recurrence (H-LR) and any recurrence.
ASA, American Society of Anesthesiologists; BMI, body mass index; CRLM, colorectal liver metastases; H-LR, hepatic local recurrence; ICU, intensive care unit; RBC, red
blood cells; UICC, Union for International Cancer Control.
* Any recurrence incudes all recurrences except H-LR.
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Table III
Association between margin status after liver resection for CRLM and site of tumor recurrence (n ¼154)
R0 (n ¼ 126) R1 (n ¼ 28) R1c (n ¼ 16) R1s (n ¼ 12) P P* Py
Site of recurrence, n (%) .748 .516 .288
H-LR only 17 (13.5) 5 (17.9) 4 (25.0) 1 (8.3)
Combined H-NLR þ H-LR 9 (7.1) 3 (10.7) 2 (12.5) 1 (8.3)
H-NLR only 17 (13.5) 4 (14.3) 3 (18.8) 1 (8.3)
Extra- and intrahepatic recurrence 51 (40.5) 12 (42.9) 4 (25.0) 8 (66.7)
Only extrahepatic recurrence 32 (25.4) 4 (14.3) 3 (18.8) 1 (8.3)
P: comparison R0 versus R1.
CRLM, colorectal liver metastases; H-LR, hepatic local recurrence; H-NLR, hepatic nonlocal recurrence R1c, R1 central lesions; R1s, R1
superficial lesions.
* P: comparison R0 versus R1c versus R1s.
y P: comparison of R1c versus R1s.
A. Andreou et al. / Surgery xxx (2020) 1e86CRLM size, bilateral tumor distribution, and the need for intra-
operative red blood cell transfusion.27 In our study, histologic
detection of tumor cells at the level of transection did not signifi-
cantly facilitate the development of more frequent H-LR or other
intrahepatic recurrence. There was also no correlation between
resection margin status and any intrahepatic or extrahepatic
pattern of recurrence.
Another finding of our study revealed that H-LR was not asso-
ciated with worse oncological outcome. OS in patients with H-LR
was not significantly different compared with OS in patients with
other intrahepatic or extrahepatic recurrence. Our results are
supported by a recent study in which OS in patients with in situ
intrahepatic recurrence did not differ from that of patients with de
novo intrahepatic recurrence.28 Our study validated this finding in
a cohort of patients undergoing only hepatectomy, while the study
from Lee et al also included patients treated with tumor ablation
and those with extrahepatic metastases.28 Similar to this study,28
our patients benefitted from modern systemic therapy thus
providing a homogeneous patient cohort for adequate evaluation of
tumor recurrence patterns.
Our study population allowed for an analysis of the impact of
liver-directed therapy for intrahepatic recurrence on long-termFig 2. Overall survival after liver resection for CRLM according to the location of tumor rec
H-LR, hepatic local recurrence; H-NLR, hepatic nonlocal recurrence.survival. Both repeat hepatectomy or ablation were compared with
palliative chemotherapy or best supportive care and revealed to be
beneficial. This finding has been recently confirmed by other studies,
which showed superior outcomes in patients selected for surgery or
ablation for intrahepatic tumor recurrence in comparison to patients
treated with chemotherapy, chemoradiation, or best supportive
care.28,29 Repeat hepatectomy for recurrent CRLM has already been
recognized as a safe and feasible procedure to improve oncologic
outcome.30 Five-year OS rates after repeat hepatectomy of up to 73%
have been reported, and re-recurrence was significantly reduced if
R0 could be performed, underlining again the role of positive sur-
gical margins as a surrogate factor for unfavorable disease.15
Furthermore, parenchymal-sparing resections (if deemed feasible
owing to the extent and location of the CRLM) increasingly allow for
repeat hepatectomies, as shown in our study.31
This retrospective study has several limitations. Firstly, preoper-
ative chemotherapy was only administered in 54.5% of patients,
whichmay have caused a certain inhomogeneity in the development
of tumor recurrence. Previous studies have demonstrated an asso-
ciation between preoperative chemotherapy and recurrence pat-
terns after resection for CRLM, such as a reduction of pulmonary
recurrences.21 However, preoperative chemotherapy was noturrence in 55 patients with intrahepatic recurrence. CRLM, colorectal liver metastases;
Fig 3. Overall survival after liver resection for CRLM according to the location of tumor recurrence in 154 patients with intra and extrahepatic recurrence. CRLM, colorectal liver
metastases, H-LR, hepatic local recurrence.
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study. Furthermore, our study was limited by the lack of data con-
cerning biomarkers such as somatic genemutations32 to validate our
hypothesis that positive resection margins represent a surrogate
factor of unfavorable disease biology. Positive RAS mutation status
has been shown previously to be associated with positive resection
margins33 and to negatively influence survival after curative resec-
tion for CRLM.20 Additionally, selection bias of patients with higher
risk of recurrence in the R1 groupwas possible resulting inworse OS.Fig 4. Overall survival after liver resection for CRLM according to the treatment of recurThis bias was made visible by the difference of major liver resections
and laparoscopic procedures between R0 and R1 cases. Likewise, the
R1 group demonstrated significantly higher postoperative morbidity
andmortality rates thatmay have contributed to the decreased OS in
this group. These results underline our hypothesis that R1 resection
represents a surrogate factor for more advanced disease and prob-
ably unfavorable tumor biology requiring extended systemic and
surgical treatment that may result in worse postoperative and long-
term outcomes. In addition, our study (Supplementary Table S1) andrence in 55 patients with intrahepatic recurrence. CRLM, colorectal liver metastases.
A. Andreou et al. / Surgery xxx (2020) 1e88previous studies have shown the negative impact of postoperative
morbidity on long-term survival after hepatetcomy for CRLM.34,35
Finally, the number of patients included in our study was too small
to stratify outcomes according to all sites of extrahepatic recurrence.
However, fusion of bicentric data and thorough evaluation of follow-
up imaging by specialized radiologists in each center contributed to
precise evaluation of intrahepatic and extrahepatic recurrent
disease.
In conclusion, our bicentric analysis indicates that R1 status is a
surrogate factor for advanced disease and does not have a direct
impact on the location of intrahepatic or extrahepatic tumor
recurrence. H-LR is not associated with worse OS compared with
other recurrences in the liver or elsewhere. Local treatment for
intrahepatic recurrence may improve long-term survival in
selected patients and therefore repeat hepatectomy and/or ablation
should be considered in case of intrahepatic disease relapse. These
findings justify (where possible) a parenchymal-sparing hepatec-
tomy in the setting of CRLM, even if an R1 outcome is deemed very
likely in the preoperative assessment.
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